Iron Leaf Capital Corp IRON 深 沪
等待开盘 11-06 09:30:00 美东时间
88.01
+1.950
+2.27%
华盛通- 最 高88.23
- 今 开85.78
- 成交量 24.81万股
- 最 低 85.135
- 昨 收 86.06
- 总市值 32.84亿
- 52周最高 95.95
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 30.82
- 委 比 -66.67%
- 总股本 3731.39万
- 历史最高 190.85
- 量 比 0.71
- 振 幅 3.60%
- 历史最低 11.60
- 每 手 1
- 风险率 9.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. (NASDAQ:IRON) will participate in fireside chats at three upcoming investor conferences: Guggenheim Second Annual Healthcare Innovation Conference on November 10th, Stifel 2025 Healthcare Conference on November 13th, and Jefferies London Healthcare Conference on November 19th. Live webcasts and archived replays will be available on the company's investor relations website. The biopharmaceutical company is focused on developing...
10-31 12:30
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
10-31 10:25
Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $115
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $115.
10-31 02:04
Disc Medicine Announces $210.9M Stock Offering
The latest update is out from Disc Medicine ( ($IRON) ). On October 20, 2025, D...
10-22 21:28
尾盘：美股涨跌不一 纳指小幅下滑
北京时间10月22日凌晨，美股周二尾盘涨跌不一，纳指小幅下滑。投资者继续关注可口可乐与3M等强劲财报，以及美国政府停摆及国际贸易关系的最新发展。 ...
10-22 02:59
Disc Medicine已定价扩大规模的证券发行
美股周二早盘，临床阶段生物制药公司Disc Medicine（IRON）股价小幅下跌，此前该公司宣布已定价扩大规模的证券发行，以筹集2.5亿美元，收益将用于...
10-21 22:57
【洞察科创板】AI、创新药藏机遇，中长期配置不改
（来源：ETF指慧家） PART.1 科创宽基指数概况 0 1 科技板块概况 上周科技板块继续回调，科创综指下跌6.08%。各细分行业也均有不同程度下...
10-20 19:56
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. (NASDAQ: IRON) announced it has started an underwritten offering of $220 million in common stock and pre-funded warrants, with $200 million from Disc and $20 million from AI DMI LLC. The company plans to use the proceeds to commercialize bitopertin for EPP and XLP, fund research and development, and for general corporate purposes. Jefferies, Leerink Partners, Morgan Stanley, and Cantor are acting as joint book-running managers...
10-20 11:00
Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones
Disc Medicine submitted a New Drug Application (NDA) for bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025, and received the FDA's Commissioner’s National Priority Voucher (CNPV), aimed at shortening the review to 1-2 months. The company expects potential approval and commercialization of bitopertin in the US by late 2025 or early 2026. Plans include advancing DISC-0974 for anemia of myelofibrosis (MF) and DISC-3405 for poly...
10-20 10:30
